Cantargia AB banner

Cantargia AB
STO:CANTA

Watchlist Manager
Cantargia AB Logo
Cantargia AB
STO:CANTA
Watchlist
Price: 4.47 SEK -11.49% Market Closed
Market Cap: kr1.1B

Cantargia AB
Investor Relations

Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

Show more
Loading
CANTA
OMX Stockholm 30
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2025
Call Date
Aug 21, 2025
Q2 2025 Earnings Call
No Analysis Available

This earnings call has not been analyzed yet.

If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.

Request Earnings Call Analysis
Earnings Call Recording
Other Earnings Calls

Management

Mr. Goran Forsberg
Chief Executive Officer
No Bio Available
Mr. Marcus Järås
Founder & Scientific Advisor
No Bio Available
Mr. Kjell Sjöström
Founder
No Bio Available
Mr. Patrik Renblad
Chief Financial Officer
No Bio Available
Dr. David Liberg
Chief Scientific Officer
No Bio Available
Nina Valkama
Executive Assistant of Administration & Finance
No Bio Available
Dr. Dominique Tersago
Chief Medical Officer
No Bio Available
Mr. Antonius Berkien
Chief Business Officer
No Bio Available
Johanna Christensen
Financial Controller
No Bio Available

Contacts

Address
SKANE
Lund
Scheelevagen 27
Contacts
+46462756260.0
www.cantargia.com